Skip to content

Cognitive · compound · regulatory review 2026-10-09

Dihexa

A human therapeutic mechanism is not established in this catalog; laboratory hypotheses do not establish clinical benefit.

The cited evidence and any approval concern the studied or labeled preparation. Oral, nasal, cosmetic and research-market versions do not inherit product approval or proven efficacy.

Editorial review 2026-10-10. source-curated; clinician review pending.

FDA product
not established
Compounding
not established
Research
investigational
Sport
unknown

What is Dihexa?

Other names in the library: none recorded. The cited evidence and any approval concern the studied or labeled preparation. Oral, nasal, cosmetic and research-market versions do not inherit product approval or proven efficacy. Listed sizes: no listed milligram sizes in the vendor file. A seller title is a listing. It does not prove the vial matches a paper.

In plain language

Dihexa is listed here as a compound. A human therapeutic mechanism is not established in this catalog; laboratory hypotheses do not establish clinical benefit. Status was checked 2026-10-09. This card reports cited facts. It does not tell you to use Dihexa or how much to take.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Identity context

Notice of Concern: McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, and Harding JW (2013) Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents, <i>J Pharmacol Exp Ther</i>, 344: 141-154; DOI: https://doi.org/10.1124/jpet.112.199497.

Rat cognition models and cells

Reported findings. Expression of concern is linked to experimental Dihexa study; findings withheld.

Nonresponse. Human efficacy not established by this source.

Harms. Disputed study is not ordinary verified benefit evidence; concern is not retraction.

Limits. Review original concern before interpreting disputed study.

Preparation: Dihexa research preparation Route: oral/IP/ICV in rats

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Lab or animal research

AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway.

Male APP/PS1 mice treated from ages6-9months for three months; maze figures12/group, tissue figures6/group.

Reported findings. Reported shorter maze escape latency, more platform crossings and improved neuronal, synaptophysin and inflammatory markers.

Nonresponse. Swimming speed unchanged.

Harms. Dedicated toxicity or adverse-event assessment unreported; safety not established.

Limits. Contradictory route wording prevents assigning oral or intraperitoneal efficacy alone. Wortmannin reversed tissue-marker effects; inhibitor-only control absent. Pathway involvement does not establish HGF/c-Met mediation. Study cites older PMID23055539, which has expression of concern34551989. That older record remains withheld; no linked notice found for this later study is not comprehensive lifecycle clearance. Retraction40312093 targets separate2014paper25187433, not this2021paper; lifecycle status is not transferred between papers.

Preparation: MedChemExpress Dihexa, N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide; lot, purity and independent identity verification unreported. Route: Unresolved: methods describe intragastric administration then intraperitoneal Dihexa; results say intragastric and discussion describes injections.

Read original source ↗

Editorial review 2026-10-10. Clinician review pending.

Lab or animal research

Effects of an AngiotensinIV Analog on3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats

40 male Wistar rats randomized tovehicle,3NP,and3NP+Dihexa; five-week toxin-inducedHD-like model.

Reported findings. No protective benefit was reported in this model.

Nonresponse. Dihexa did not protect against toxin-associated weight-gain,spatial-learning/memory or motor deficits.

Harms. Dedicated compound harms assessment unverified in accessible abstract; toxin-related deficits cannot be labeled Dihexa toxicity.

Limits. A toxin rat model is not genetically confirmed humanHD or a human efficacy test. This is an independent later experiment with nulls, not a lifecycle correction or causal rebuttal of every positive Dihexa paper. Fresh EuropePMC metadata has no linked correction/retraction; original publisher preview does not show notice, comprehensive clearance not asserted. Original publisher abstract/date accessed via web tool; guarded raw publisher fetch403 was stopped. Full methods,funding/COI and peptide delivery route unavailable.

Preparation: PNB0408 explicitly identified in original abstract as Dihexa/N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide; study preparation identity claim, not batch validation. Route: Dihexa route not specified in reviewed primary abstract. Systemic route wording describes neurotoxin, not automatically Dihexa.

Read original source ↗

Editorial review 2026-10-10. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

not established. No US therapeutic product approval is established by this curated source set; other countries and products may differ.

Compounding

not established. Compounded products do not carry FDA product approval; legal eligibility is not established here.

Research

investigational. FDA reports no identified human exposure data; efficacy is not established.

Sport

unknown. Not individually verified; consult the current sport rules. Absence of a listing is not permission.

How long it lasts, how you store it, listed sizes

This entry doesn’t give a duration in hours. No verified formulation-specific human estimate in this source set; no guessed value is supplied.

Half-life on file: no single hour value. No verified formulation-specific human estimate in this source set; no guessed value is supplied. Follow the label on the vial you hold. This page does not set a throw-away date after you add water.

This card has no units chart until a milligram size is listed.

Risks and mix-ups already on the record

  • Human exposure and safety data are absent.
  • Unknown or incomplete for research formulations; this is not a clearance for use.
  • Unknown or incomplete; do not infer compatibility with medications or other substances.

People using PepBear often log: Existing clinician-directed records, symptoms and dated health measurements. Record missing data; trends do not demonstrate causation.

Sources

  1. Primary evidence or regulator source · checked 2026-10-09

Questions people ask

Is Dihexa FDA-approved?

not established. No US therapeutic product approval is established by this curated source set; other countries and products may differ.

Does PepBear pick an amount of Dihexa?

The calculator turns numbers you type into U-100 units. Trial or label amounts stay as cited facts.

Related cards

A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.

Optional merchant comparison

Where to buy Dihexa

Compare the same identity, formulation and format. Blends, oral products and different variants stay separate. A lower price does not establish product quality or medical suitability.

We earn a commission when you buy through PepStar LLC partner links or codes RICHPEP and PEPBEAR. Merchant listings are separate from the evidence and do not establish product quality or medical suitability.

No exact product listing is verified for this identity yet.